How CAR T Cells Can Change the Treatment Landscape for Non-Hodgkin LymphomaNovember 5th 2019
David Maloney, MD, PhD, medical director, Cellular Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, discusses the results of the ZUMA trial and how chimeric antigen receptor CAR T-cell therapy is changing the treatment landscape for non-Hodgkin lymphoma.
Analyzing Real-World Data for CAR T-Cell Therapy in Patients With ALL and DLBCLOctober 7th 2019
Marcelo C. Pasquini, MD, discusses the rationale for analyzing real-world data for the use of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma. This CD19 CAR T cell was approved 2 years ago for use in both ALL and DLBCL.
Annual Hematology Meeting Cochair Encourages Embracing of CAR T-Cell TherapySeptember 24th 2019
Now in it 24th year, the annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma, hosted by Physicians’ Education Resource, LLC, continues to bring significant advances in hematology to the forefront.
Expert Suggests Novel Approaches To Improve CAR Therapies in ALLSeptember 13th 2019
To improve the efficacy of chimeric antigen receptor T-cell therapies, Nirali N. Shah, MD, MHSc, suggested including new constructs that target more than 1 antigen in patients with acute lymphoblastic leukemia, during a presentation at the 2019 SOHO Annual Meeting.<br />
Neelapu Discusses Toxicities Associated With CAR T Cells in Large B-Cell LymphomasAugust 29th 2019
In an interview with Targeted Oncology, Sattva S. Neelapu, MD, discussed the evolving role for CAR T-cell therapy in patients with B-cell lymphomas. He also highlighted the toxicities commonly associated with these therapies and how physicians can treat these AEs as they arise.
CAR T-Cell Therapy Poised to Become Routine Care in CLLAugust 13th 2019
The initial pilot study of CTL019 in heavily pretreated CD19-positive hematologic malignancies demonstrated the feasibility of CAR T-cell therapy in patients with CLL. A presentation at the 2019 American Society of Gene & Cell Therapy Annual Meeting reported 2 cases of chemotherapy-resistant CLL, with ongoing follow- up at 8 years showing persistence of CAR-engineered T cells and sustained remission, as determined by flow cytometry and deep sequencing of immunoglobulin H rearrangements.
Four-Year Follow-Up Data Confirm Durable Responses With CAR T-Cell Therapy in B-Cell LymphomasAugust 7th 2019
In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.
MRD Reported Undetectable After Liso-cel CAR T-cell Therapy in CLLAugust 2nd 2019
In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.
Assessing the Role CAR T-cell Therapy Plays in Mantle Cell Lymphoma Treatment in ZUMA-2 TrialJuly 31st 2019
Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with <em>Targeted Oncology</em>.
High Response Rate Seen With Concurrent Ibrutinib Plus CAR T-Cell Therapy in High-Risk CLLJune 26th 2019
Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib. Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.
Coverage Concerns Temper Enthusiasm Surrounding CAR T-Cell TreatmentApril 12th 2019
A discussion between regulators and special interest groups has cooled some of the excitement generated by the emergence of chimeric antigen receptor T-cell therapy for treating hematologic cancers.
Challenges Persist With CAR T-Cell Therapy in Pancreatic CancerApril 2nd 2019
The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.
I-O Combo of Checkpoint Inhibitor With CAR T-Cell Therapy Shows Promise in Relapsed B-Cell ALLDecember 3rd 2018
According to results from a small clinical study, checkpoint inhibitors in combination with chimeric antigen receptor T-cell therapy showed promise for improving CAR T-cell persistance in some patients with relapsed B-cell acute lymphoblastic leukemia. <br />
Risk of Relapse Reduced With HCT Following CAR T-Cell Therapy in ALLDecember 2nd 2018
Patients with acute lymphoblastic leukemia saw a reduction in the risk for recurrence after receiving a stem cell transplant for the first time following treatment with CD19 chimeric antigen receptor T-cell therapy.
High Response Rate Found in CLL With Ibrutinib/CAR T-Cell ComboDecember 2nd 2018
According to a retrospective phase I/II study, over 80% of patients with relapsed or refractory chronic lymphocytic leukemia responded to concurrent treatment with ibrutinib and the CD19-targeted chimeric antigen receptor CAR T-cell therapy, JCAR014.<sup>1</sup> Findings from this study were presented at the 60th American Society of Hematology Annual Meeting.